Treatment of amyotrophic lateral sclerosis (ALS) with ibudilast
AssigneeMediciNova, Inc.
InventorsMichael E. Kalafer, Kenneth W. Locke, Kazuko Matsuda, Richard E. Gammans
Life of this patent
Estimating the term…
Abstract
Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
Claims12
A method of treating a patient diagnosed with amyotrophic lateral sclerosis (ALS) comprising administering to said patient a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof ranging between 1-240 mg/day.
A method of treating a patient diagnosed with amyotrophic lateral sclerosis (ALS) comprising administering to said patient a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof ranging between about 0.1 and 200 mg/day.
Dependencies are inferred from the claim text.